A new study published in The New England Journal of Medicine showed that daily dapagliflozin dramatically reduced the risk of ...

A randomized controlled trial investigated use of sodium glucose cotransporter 2 inhibitors (SGLT2i) on top of standard care immunosuppression in lupus nephritis.

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...

Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...

Dapagliflozin, the type 2 diabetes (T2D) therapy that recently received an indication in heart failure (HF), meets all 3 criteria for managing the condition outlined in an FDA draft guidance for ...

Kato E, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus based on ejection fraction [published online March 18, 2019]. Circulation. Verma S, McMurray JJV.

Dapagliflozin is usually given along with diet and exercise. The drug mainly acts by causing the kidneys to get rid of glucose in the urine. More info about Dapagliflozin Last Updated on Nov 08, 2024 ...

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin reduces the risk for hospitalization among patients with nondialysis-dependent chronic kidney disease, a new analysis confirms. In a post hoc analysis of the DAPA-CKD (Dapagliflozin ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...